Aclarion, Inc. announced that CEO Brent Ness will attend LSI USA 2026, a leading conference for MedTech innovators, investors, and industry leaders. During the event, Ness will meet with investors and potential partners to discuss progress on Nociscan, the company's proprietary magnetic resonance spectroscopy platform that uses augmented intelligence algorithms and biomarkers to help physicians distinguish between painful and non-painful discs in chronic low back pain patients.
The conference represents a significant opportunity for Aclarion to showcase its technology to key stakeholders in the healthcare innovation ecosystem. LSI USA 2026, scheduled for March 16-20 in Dana Point, California, focuses on accelerating MedTech and HealthTech innovation through in-person meetings between startups, investors, and industry leaders. For more information about the company's developments, readers can visit the Aclarion newsroom.
Nociscan represents a novel approach to addressing chronic low back pain, a condition affecting millions worldwide and representing a substantial healthcare burden. The platform operates as a software-as-a-service (SaaS) solution that receives magnetic resonance spectroscopy data from MRI machines via cloud connection. Proprietary signal processing techniques then extract and quantify chemical biomarkers associated with disc pain, which are analyzed through AI algorithms to indicate potential pain sources.
The technology's implications for clinical practice are substantial. By providing objective data about which specific discs may be causing pain, Nociscan could help physicians develop more targeted treatment strategies, potentially reducing unnecessary procedures and improving patient outcomes. This precision diagnostic approach aligns with broader trends in personalized medicine and data-driven healthcare.
For the medical technology industry, Aclarion's platform demonstrates how AI and biomarker analysis can be combined to address complex diagnostic challenges. The company's focus on chronic low back pain targets a market with significant unmet needs, where current diagnostic methods often rely on subjective patient reporting and may not accurately identify pain sources. Additional coverage of this announcement is available through PRISM MediaWire on Newsramp.
The business implications extend beyond clinical applications. As a commercial-stage company trading on Nasdaq under symbols ACON and ACONW, Aclarion's participation in LSI USA 2026 represents a strategic effort to build partnerships and secure investment for further development and commercialization. Success in this market could establish new standards for chronic pain diagnosis and create substantial value in the growing digital health sector.
For healthcare leaders and technology executives, Aclarion's approach illustrates how emerging technologies can be applied to longstanding medical challenges. The integration of cloud computing, AI algorithms, and biomarker science represents a convergence of multiple technological trends with potential to transform diagnostic paradigms. As the company advances its clinical validation and commercial deployment, its progress will be closely watched by investors, healthcare providers, and competitors in the medical technology space.
